The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease
- 31 May 2009
- journal article
- Published by Elsevier BV in Neurobiology of Aging
- Vol. 30 (5), 672-681
- https://doi.org/10.1016/j.neurobiolaging.2007.08.019
Abstract
No abstract availableKeywords
This publication has 65 references indexed in Scilit:
- Prediction and longitudinal study of CSF biomarkers in mild cognitive impairmentNeurobiology of Aging, 2009
- No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer's diseaseBrain, 2007
- No association of CSF biomarkers with APOE 4, plaque and tangle burden in definite Alzheimer's diseaseBrain, 2007
- Amyloid β peptide ratio 42/40 but not Aβ42 correlates with phospho‐Tau in patients with low‐ and high‐CSF Aβ40 loadJournal of Neurochemistry, 2006
- Alzheimer's diseaseThe Lancet, 2006
- Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up studyThe Lancet Neurology, 2006
- Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimer’s diseaseJournal of Neural Transmission, 2004
- Oxidative Stress and Neuronal Adaptation in Alzheimer Disease: The Role of SAPK PathwaysAntioxidants and Redox Signaling, 2003
- Differences in the A?40/A?42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotypeAnnals of Neurology, 2000
- Platelets Are the Primary Source of Amyloid β-Peptide in Human BloodBiochemical and Biophysical Research Communications, 1995